As if Amarin Corporation PLC Needs Another Worry, Here Comes a Vascepa FDA Panel

Published: Jun 07, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Amarin (AMRN_) President John Thero made news -- and not necessarily the good kind -- at an investor conference Thursday when he said the company was preparing for a Vascepa FDA advisory panel later this year. A date for the FDA advisory panel has not been set, but Thero said the panel would review Amarin's prescription-grade fish oil pill for the so-called "Anchor" indication of treating patients with mixed dyslipidemia.

Help employers find you! Check out all the jobs and post your resume.

Back to news